Detail for Flucytosine
Basic Information
DrugID 51
DrugName Flucytosine
DrugDetail Flucytosine, or 5-fluorocytosine, a fluorinated pyrimidine analogue, is a synthetic antimycotic drug. It is structurally related to the cytostatic fluorouracil and to floxuridine. It is available in oral and in some countries also in injectable form. A common brand name is Ancobon. Flucytosine was first synthesized in 1957 but its antifungal properties discovered in 1964. The drug is dispensed in capsules of 250 mg and 500 mg strength. The injectable form is diluted in 250 mL saline solution to contain 2.5 g total (10 mg/mL). The solution is physically incompatible with other drugs including amphotericin B.

http://en.wikipedia.org/wiki/Flucytosine

Indication For the treatment (in combination with amphotericin B) of serious infections caused by susceptible strains of Candida (septicemia, endocarditis and urinary system infections) and/or Cryptococcus (meningitis and pulmonary infections).

http://www.drugbank.ca/drugs/DB01099

Structure Click to see the orginal picture.
Interaction
Drug Name PMIDLink Reference
Amphotericin B Schwarz P, Dromer F, Lortholary O, Dannaoui E. (2006) Efficacy of amphotericin B in combination withagainst flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother. 50(1):113-20.
Amphotericin B Schwarz P, Dromer F, Lortholary O, Dannaoui E. (2003) In vitro interaction ofwith conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother. 47(10):3361-4.
Amphotericin B Schwarz P, Janbon G, Dromer F, Lortholary O, Dannaoui E. (2007) Combination of amphotericin B withis active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob Agents Chemother. 51(1):383-5.
Caspofungin Schwarz P, Dromer F, Lortholary O, Dannaoui E. (2003) In vitro interaction ofwith conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother. 47(10):3361-4.
Caspofungin Dannaoui E, Lortholary O, Dromer F. (2004) In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother. 48(3):970-8.
Fluconazole Schwarz P, Dromer F, Lortholary O, Dannaoui E. (2003) In vitro interaction ofwith conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother. 47(10):3361-4.
Fluconazole Nguyen MH, Barchiesi F, McGough DA, Yu VL, Rinaldi MG. (1995) In vitro evaluation of combination of fluconazole andagainst Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother. 39(8):1691-5.
Itraconazole Schwarz P, Dromer F, Lortholary O, Dannaoui E. (2003) In vitro interaction ofwith conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother. 47(10):3361-4.
Posaconazole Barchiesi F, Schimizzi AM, Najvar LK, Bocanegra R, Caselli F, Di Cesare S, Giannini D, Di Francesco LF, Giacometti A, Carle F, Scalise G, Graybill JR. (2001) Interactions of posaconazole andagainst Cryptococcus neoformans. Antimicrob Agents Chemother. 45(5):1355-9.
Voriconazole Schwarz P, Dromer F, Lortholary O, Dannaoui E. (2003) In vitro interaction ofwith conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother. 47(10):3361-4.
Fluconazole Schwarz P., Dromer F., Lortholary O., Dannaoui E. (2003) In vitro interaction ofwith conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrobial Agents and Chemotherapy 47:3361-3364. DOI: 10.1128/aac.47.10.3361-3364.2003
Amphotericin B Schwarz P., Dromer F., Lortholary O., Dannaoui E. (2003) In vitro interaction ofwith conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrobial Agents and Chemotherapy 47:3361-3364. DOI: 10.1128/aac.47.10.3361-3364.2003
Voriconazole Schwarz P., Dromer F., Lortholary O., Dannaoui E. (2003) In vitro interaction ofwith conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrobial Agents and Chemotherapy 47:3361-3364. DOI: 10.1128/aac.47.10.3361-3364.2003
Caspofungin Schwarz P., Dromer F., Lortholary O., Dannaoui E. (2003) In vitro interaction ofwith conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrobial Agents and Chemotherapy 47:3361-3364. DOI: 10.1128/aac.47.10.3361-3364.2003
Itraconazole Schwarz P., Dromer F., Lortholary O., Dannaoui E. (2003) In vitro interaction ofwith conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrobial Agents and Chemotherapy 47:3361-3364. DOI: 10.1128/aac.47.10.3361-3364.2003
Micafungin Nishi I., Sunada A., Toyokawa M., Asari S., Iwatani Y. (2009) In vitro antifungal combination effects ofwith fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species (vol 15, pg 1, 2009). Journal of Infection and Chemotherapy 15:123-124. DOI: 10.1007/s10156-009-0002-7
Target
PathWay